Zenas BioPharma, Inc.

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma granted 74,900 RSUs to newly hired employees on October 15, 2026, as inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments through 2030 and are tied to continued service with the company. This is a routine new-hire equity disclosure with no bearing on the company's clinical programs or financial condition.

•16d ago

Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis Portfolio Data at MSToronto2026

Zenas BioPharma will present seven posters on orelabrutinib and obexelimab in multiple sclerosis at the 10th Joint ACTRIMS-ECTRIMS Meeting (MSToronto2026), October 21-23, 2026, in Toronto. The data include 24-week Phase 2 results for orelabrutinib and obexelimab in relapsing MS, plus designs of the Phase 3 Monarch (non-active SPMS) and PriMroSe (PPMS) trials of orelabrutinib. The company will also host an expert symposium on BTK inhibition in progressive MS. No new clinical results are disclosed in this release; investors will watch the poster session on October 22 and the SunStone Phase 2 SLE topline expected in 4Q 2026.

•25d ago

Zenas BioPharma to Host Virtual R&D Event

Zenas BioPharma will host a virtual R&D event on Tuesday, October 27, 2026, from 8:00 to 9:30 a.m. ET. Presentations will cover the pipeline including obexelimab, the company's bifunctional CD19/FcγRIIb antibody in systemic lupus erythematosus, and ZB021, an oral IL-17AA/AF inhibitor, with Dr. Joseph Merola providing clinical insights. The notice contains no new clinical or financial data; the event may preview obexelimab topline timing in SLE.

•26d ago

Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026

Zenas BioPharma (Nasdaq: ZBIO) said new data from the Phase 3 INDIGO trial of obexelimab in IgG4-related disease will be presented at the 6th International Symposium on IgG4-Related Disease (October 8-10, Cambridge, MA) and ACR Convergence 2026 (November 6-11, Orlando, FL). The lineup includes longer-term flare protection and safety data from the INDIGO open-label extension, plus analyses of glucocorticoid-associated toxicity and of influenza and SARS-CoV-2 vaccine responses in treated patients. Obexelimab has been evaluated in nine clinical trials totaling 667 subjects; IgG4-RD affects roughly 20,000 diagnosed patients in the US, with true prevalence estimated closer to 40,000. The release contains no new topline data and mainly reiterates that Phase 2 SunStone topline results in systemic lupus erythematosus are expected in 4Q 2026, the company's next major catalyst.

•1mo ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma granted inducement equity awards to newly hired employees on September 15, 2026, under Nasdaq Listing Rule 5635(c)(4). The awards consist of non-qualified stock options to purchase 53,700 shares at an exercise price of $31.93 and 98,900 RSUs, each vesting over four years under the company's 2026 Inducement Plan. These grants are standard new-hire compensation disclosures and contain no new information on Zenas' clinical pipeline, including its lead candidates obexelimab and orelabrutinib.

•1mo ago

Zenas BioPharma to Host Obexelimab IgG4-RD Investor Event

Zenas BioPharma will host a virtual investor event on obexelimab in IgG4-Related Disease on Tuesday, September 29, 2026, from 8:00 to 9:30 a.m. ET. Management will be joined by Dr. Guy Katz of Massachusetts General Hospital and plans to cover the IgG4-RD treatment landscape, prelaunch preparedness strategies, and the potential commercial opportunity for obexelimab if approved by the FDA. The FDA accepted Zenas' Biologics License Application for obexelimab in IgG4-RD in August 2026 with a PDUFA target action date of May 27, 2027, and the company expects to submit a Marketing Authorization Application to the EMA in the second half of 2026.

•1mo ago

Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences

Zenas BioPharma announced management presentations at three upcoming healthcare investor conferences: the Citi Biopharma Back to School Conference on September 9, the Morgan Stanley 24th Annual Global Healthcare Conference on September 14, and the H.C. Wainwright 28th Annual Global Investment Conference on September 16, 2026. Live webcasts and archived replays will be available in the Events and Presentations section of the company website; the release contains no new clinical, financial, or guidance disclosures. Zenas is a clinical-stage biopharmaceutical company advancing two late-stage candidates, obexelimab and orelabrutinib, for autoimmune and inflammatory diseases, alongside earlier-stage programs ZB021, ZB022, and ZB014.

•1mo ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma granted an aggregate of 11,000 restricted stock units to newly hired employees as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The RSUs will vest in four equal annual installments beginning on August 15, 2027, subject to the employees' continued service with the company.

•2mo ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma granted inducement awards to new employees on July 15, 2026, consisting of 35,750 non-qualified stock options and 79,050 restricted stock units. The stock options have a ten-year term and an exercise price of $29.41 per share, matching the closing price on the grant date. Both the options and RSUs will vest over a four-year period, with options vesting monthly after the first year and RSUs vesting in equal annual installments beginning in 2027.

•3mo ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma granted non-qualified stock options and restricted stock units to new employees as an employment inducement on June 15, 2026. The awards consist of 100,000 stock options with an exercise price of $18.71 and 78,075 RSUs, both subject to four-year vesting schedules. These grants were made in accordance with Nasdaq Listing Rule 5635(c)(4) and the company’s 2026 Inducement Plan.

•4mo ago

Zenas BioPharma to Present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit

Zenas BioPharma will present at the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit. The presentation will be available on-demand starting June 15, 2026, at 7:00 a.m. ET. No new clinical data or regulatory milestones were disclosed in this announcement.

•4mo ago

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma granted 51,075 restricted stock units to newly hired employees as inducement awards under Nasdaq Listing Rule 5635(c)(4). The RSUs vest in four equal annual installments starting May 15, 2027, contingent on continued service. This is a routine compliance disclosure for standard employee compensation and does not signal new capital raising or strategic changes.

•5mo ago